Protein methyltransferase inhibitors as precision cancer therapeutics: a decade of discovery
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Protein methyltransferase inhibitors as precision cancer therapeutics: a decade of discovery
Authors
Keywords
-
Journal
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
Volume 373, Issue 1748, Pages 20170080
Publisher
The Royal Society
Online
2018-04-23
DOI
10.1098/rstb.2017.0080
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex
- (2017) Yupeng He et al. Nature Chemical Biology
- The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity
- (2017) Kenneth D Bromberg et al. Nature Chemical Biology
- Discovery of a Potent and Selective Coactivator Associated Arginine Methyltransferase 1 (CARM1) Inhibitor by Virtual Screening
- (2016) Renato Ferreira de Freitas et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting EZH2 in cancer
- (2016) Kimberly H Kim et al. NATURE MEDICINE
- A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases
- (2015) Mohammad S. Eram et al. ACS Chemical Biology
- A Potent, Selective and Cell-Active Allosteric Inhibitor of Protein Arginine Methyltransferase 3 (PRMT3)
- (2015) H. Ümit Kaniskan et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo
- (2015) Dmitry Borkin et al. CANCER CELL
- Mixed lineage rearranged leukaemia
- (2015) Eytan M. Stein et al. CURRENT OPINION IN HEMATOLOGY
- Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention
- (2015) Chen Shen et al. CURRENT OPINION IN ONCOLOGY
- 302 A phase 1 study of EPZ-6438 (E7438), an Enhancer of Zeste-Homolog 2 (EZH2) inhibitor: Preliminary activity in INI1-negative tumors
- (2015) A. Italiano et al. EUROPEAN JOURNAL OF CANCER
- Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains
- (2015) Junwei Shi et al. NATURE BIOTECHNOLOGY
- A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
- (2015) Elayne Chan-Penebre et al. Nature Chemical Biology
- The drug–target residence time model: a 10-year retrospective
- (2015) Robert A. Copeland NATURE REVIEWS DRUG DISCOVERY
- Aryl Pyrazoles as Potent Inhibitors of Arginine Methyltransferases: Identification of the First PRMT6 Tool Compound
- (2015) Lorna H. Mitchell et al. ACS Medicinal Chemistry Letters
- Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor
- (2015) Lorna H. Mitchell et al. ACS Medicinal Chemistry Letters
- Reaction Coupling between Wild-Type and Disease-Associated Mutant EZH2
- (2014) Brooke M. Swalm et al. ACS Chemical Biology
- Small Molecule Control of Chromatin Remodeling
- (2014) Aidan Finley et al. CHEMISTRY & BIOLOGY
- Trimethylation of Histone H3 Lysine 36 by Human Methyltransferase PRDM9 Protein
- (2014) Mohammad S. Eram et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of a Selective, Substrate-Competitive Inhibitor of the Lysine Methyltransferase SETD8
- (2014) Anqi Ma et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
- (2014) S. K. Knutson et al. MOLECULAR CANCER THERAPEUTICS
- (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells
- (2014) D. Barsyte-Lovejoy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
- (2013) S. R. Daigle et al. BLOOD
- Molecular Pathways: Protein Methyltransferases in Cancer
- (2013) R. A. Copeland CLINICAL CANCER RESEARCH
- Discovery of an in Vivo Chemical Probe of the Lysine Methyltransferases G9a and GLP
- (2013) Feng Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Chromatin proteins and modifications as drug targets
- (2013) Kristian Helin et al. NATURE
- Targeted disruption of the EZH2–EED complex inhibits EZH2-dependent cancer
- (2013) Woojin Kim et al. Nature Chemical Biology
- Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
- (2013) S. K. Knutson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MMSET is the key molecular target in t(4;14) myeloma
- (2013) F Mirabella et al. Blood Cancer Journal
- Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L
- (2012) Aravind Basavapathruni et al. Chemical Biology & Drug Design
- A687V EZH2 is a gain-of-function mutation found in lymphoma patients
- (2012) Christina R. Majer et al. FEBS LETTERS
- Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells
- (2012) Irina Alimova et al. NEURO-ONCOLOGY
- Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
- (2012) M. T. McCabe et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
- (2011) Scott R. Daigle et al. CANCER CELL
- MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
- (2011) Kathrin M. Bernt et al. CANCER CELL
- Chemogenetic Analysis of Human Protein Methyltransferases
- (2011) Victoria M. Richon et al. Chemical Biology & Drug Design
- Identification of Protein N-Terminal Methyltransferases in Yeast and Humans
- (2010) Kristofor J. Webb et al. BIOCHEMISTRY
- Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation
- (2010) D. B. Yap et al. BLOOD
- Protein Lysine Methyltransferase G9a Inhibitors: Design, Synthesis, and Structure Activity Relationships of 2,4-Diamino-7-aminoalkoxy-quinazolines.
- (2010) Feng Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
- (2010) Ryan D Morin et al. NATURE GENETICS
- Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas
- (2010) C. J. Sneeringer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Condensed DNA: Condensing the concepts
- (2010) Vladimir B. Teif et al. PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY
- Epigenetic Dysregulation in Cancer
- (2009) Andrew G. Muntean et al. AMERICAN JOURNAL OF PATHOLOGY
- Protein methyltransferases as a target class for drug discovery
- (2009) Robert A. Copeland et al. NATURE REVIEWS DRUG DISCOVERY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started